Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy.

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

The drug is cleared by cytochrome P450 (CYP ... Blood levels of eplerenone are increased by inhibitors of CYP3A4, such as ketoconazole and saquinavir. About 50% is bound by plasma protein.

SaveHealth assesses the relative benefits of Zoloft vs. Lexapro, comparing their usage, effectiveness, tolerability, ...

When a medication works right, it boosts your health or helps you feel better. But a drug can bring on problems if it doesn't mix well with something else you put into your body, like another ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

Figure 1 lists the pharmacokinetic drug interactions with smoking. The most clinically significant interactions appear in the shaded rows and are discussed below.

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

Apr. 15, 2025 — Researchers have developed a machine learning workflow to optimize the output force of photo-actuated organic crystals. Using LASSO regression to ...

The FDA requires most OTC and prescription drug tablets and capsules to have an imprint. This code -- combined with the pill’s size, color, and shape -- helps you tell it apart from other ...

Bayer will present new data from the ARANOTE trial evaluating ultra-low prostate-specific antigen responses with NUBEQA ® ...